JP6754353B2 - ハンチントンタンパク質のイメージング用プローブ - Google Patents

ハンチントンタンパク質のイメージング用プローブ Download PDF

Info

Publication number
JP6754353B2
JP6754353B2 JP2017511926A JP2017511926A JP6754353B2 JP 6754353 B2 JP6754353 B2 JP 6754353B2 JP 2017511926 A JP2017511926 A JP 2017511926A JP 2017511926 A JP2017511926 A JP 2017511926A JP 6754353 B2 JP6754353 B2 JP 6754353B2
Authority
JP
Japan
Prior art keywords
pyridine
methoxy
carbonitrile
benzofuran
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017511926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529340A (ja
JP2017529340A5 (enExample
Inventor
ドミンゲス，セリア
ウィチャック，ジョン
バード，ジョナサン
キセリョーフ，アレックス
ブラウン，クリストファー，ジョン
プライム，マイケル，エドワード
ジョンソン，ピーター，デーヴィッド
クラーク−フルー，ダニエル
Original Assignee
シーエイチディーアイ ファウンデーション，インコーポレーテッド
シーエイチディーアイ ファウンデーション，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエイチディーアイ ファウンデーション，インコーポレーテッド, シーエイチディーアイ ファウンデーション，インコーポレーテッド filed Critical シーエイチディーアイ ファウンデーション，インコーポレーテッド
Publication of JP2017529340A publication Critical patent/JP2017529340A/ja
Publication of JP2017529340A5 publication Critical patent/JP2017529340A5/ja
Application granted granted Critical
Publication of JP6754353B2 publication Critical patent/JP6754353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017511926A 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ Active JP6754353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
US62/043,590 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (3)

Publication Number Publication Date
JP2017529340A JP2017529340A (ja) 2017-10-05
JP2017529340A5 JP2017529340A5 (enExample) 2018-10-11
JP6754353B2 true JP6754353B2 (ja) 2020-09-09

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511926A Active JP6754353B2 (ja) 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ

Country Status (20)

Country Link
US (2) US11104691B2 (enExample)
EP (1) EP3197277B1 (enExample)
JP (1) JP6754353B2 (enExample)
KR (1) KR102410733B1 (enExample)
CN (1) CN107105667B (enExample)
AU (2) AU2015308769A1 (enExample)
BR (1) BR112017004140B1 (enExample)
CA (1) CA2959533C (enExample)
DK (1) DK3197277T3 (enExample)
EA (1) EA039923B1 (enExample)
ES (1) ES2905095T3 (enExample)
HR (1) HRP20220001T1 (enExample)
HU (1) HUE057702T2 (enExample)
IL (1) IL250802B (enExample)
MX (1) MX386798B (enExample)
PL (1) PL3197277T3 (enExample)
PT (1) PT3197277T (enExample)
SG (1) SG11201701592SA (enExample)
SI (1) SI3197277T1 (enExample)
WO (1) WO2016033440A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
US20190381030A1 (en) * 2017-10-12 2019-12-19 University Of Kansas Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using yel002/bcn057
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
AU2020267664B2 (en) 2019-05-09 2023-04-27 F. Hoffmann-La Roche Ag Synthesis of labeled imidazo[1,2-A]pyrimidines
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2004265174A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probe for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles.
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
KR20090091287A (ko) * 2006-11-17 2009-08-27 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
NZ577511A (en) * 2006-11-30 2012-04-27 Nihon Mediphysics Co Ltd 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a radioactive halogen substituent
CA2676214A1 (en) * 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives
WO2009057577A1 (ja) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物の使用及び製造方法
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
BRPI0919079B1 (pt) * 2008-09-23 2022-02-15 Wista Laboratories Ltd Métodos para marcar filamentos helicoidais pareados (phfs), e para marcar tau agregado, bem como compostos ligantes para moléculas tau agregadas
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
AU2012259929B2 (en) * 2011-05-20 2016-08-04 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) * 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
JP2013237655A (ja) * 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
BR112015010469A2 (pt) * 2012-11-14 2017-07-11 Hoffmann La Roche derivados de imidazopiridina
SI2970255T1 (sl) 2013-03-14 2017-12-29 Galapagos Nv Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj
MX2016003422A (es) * 2013-09-26 2016-06-28 Hoffmann La Roche Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Also Published As

Publication number Publication date
US11104691B2 (en) 2021-08-31
SG11201701592SA (en) 2017-03-30
EP3197277B1 (en) 2021-12-22
WO2016033440A1 (en) 2016-03-03
HUE057702T2 (hu) 2022-05-28
IL250802B (en) 2020-08-31
IL250802A0 (en) 2017-04-30
CA2959533C (en) 2023-03-07
CN107105667A (zh) 2017-08-29
AU2015308769A1 (en) 2017-03-23
US11851446B2 (en) 2023-12-26
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
KR102410733B1 (ko) 2022-06-20
EP3197277A4 (en) 2018-04-18
EA201790400A1 (ru) 2017-09-29
EA039923B1 (ru) 2022-03-28
MX386798B (es) 2025-03-19
AU2019283999B2 (en) 2021-07-22
PL3197277T3 (pl) 2022-04-04
PT3197277T (pt) 2022-02-01
KR20170047303A (ko) 2017-05-04
JP2017529340A (ja) 2017-10-05
CN107105667B (zh) 2021-08-17
SI3197277T1 (sl) 2022-04-29
US20210380608A1 (en) 2021-12-09
BR112017004140A2 (pt) 2017-12-12
MX2017002702A (es) 2017-10-23
US20170283439A1 (en) 2017-10-05
AU2019283999A1 (en) 2020-01-23
CA2959533A1 (en) 2016-03-03
BR112017004140B1 (pt) 2023-01-10
ES2905095T3 (es) 2022-04-07
DK3197277T3 (da) 2022-01-31

Similar Documents

Publication Publication Date Title
JP7126541B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP6754353B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP7042940B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP6944929B2 (ja) ハンチントンタンパク質のイメージング用プローブ
US10907197B2 (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200821

R150 Certificate of patent or registration of utility model

Ref document number: 6754353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250